Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Pharmacogenomics and cardiovascular disease

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Symptoms Preceding Sports-Related Sudden Cardiac Death in Persons Aged 1-49 Years

    Research output: Contribution to journalReviewpeer-review

  2. Diagnosis and Management of Lymphatic Disorders in Congenital Heart Disease

    Research output: Contribution to journalReviewpeer-review

  3. Diabetes and the Risk of Sudden Cardiac Death

    Research output: Contribution to journalReviewpeer-review

  1. Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Risk of diabetes among related and unrelated family members

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Variability in drug responsiveness is a sine qua non of modern therapeutics, and the contribution of genomic variation is increasingly recognized. Investigating the genomic basis for variable responses to cardiovascular therapies has been a model for pharmacogenomics in general and has established critical pathways and specific loci modulating therapeutic responses to commonly used drugs such as clopidogrel, warfarin, and statins. In addition, genomic approaches have defined mechanisms and genetic variants underlying important toxicities with these and other drugs. These findings have not only resulted in changes to the product labels but also have led to development of initial clinical guidelines that consider how to facilitate incorporating genetic information to the bedside. This review summarizes the state of knowledge in cardiovascular pharmacogenomics and considers how variants described to date might be deployed in clinical decision making.
Original languageEnglish
JournalCurrent Cardiology Reports (Print)
Volume15
Issue number7
Pages (from-to)376
ISSN1534-3170
DOIs
Publication statusPublished - Jul 2013

ID: 38907909